Calidi Biotherapeutics presented its latest developments in antitumor virotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting.
NeuroNova (CLD-101):
• Phase 1 study for recurrent high-grade gliomas has progressed, demonstrating safety and feasibility.
• Four weekly doses of CLD-101 are being administered, and no adverse events have been reported in cohorts 2 and 3.
• Enrollment is ongoing for the fourth cohort.
RTNova (CLD-400):
• Preclinical data shows that CLD-400 can survive in the bloodstream and reach all tumors systemically.
• This technology enables targeted delivery of oncolytic viruses to multiple tumor sites.
SuperNova (CLD-201):
• Non-clinical data supports the upcoming Phase 1 clinical trial of CLD-201.
• CLD-201’s cell-based oncolytic virotherapy aims to treat multiple solid tumors.
• An IND application with the FDA will be filed to initiate the trial in the future.
Calidi’s cutting-edge approach to antitumor virotherapy utilizes a combination of neural stem cells and oncolytic viruses to target and destroy cancer cells selectively. The safety and progress observed in the NeuroNova program reinforce the potential of this therapy for challenging brain tumors.
The RTNova and SuperNova platforms aim to extend the benefits of oncolytic virotherapy by enabling systemic delivery and targeting a broad range of solid tumors. The positive preclinical data supports Calidi’s plans for further clinical development of these novel technologies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
